CCM
IBRX icon

Carlson Capital Management’s ImmunityBio IBRX Stock Holding History

Carlson Capital Management’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		$51.2K Buy
20,000
+1,000
+5% +$4.17K ﹤0.01% 111
2024
Q3 		$70.7K Buy
19,000
+390
+2% +$1.8K ﹤0.01% 114
2024
Q2 		$118K Buy
18,610
+810
+5% +$5.34K 0.01% 105
2024
Q1 		$95.6K Buy
17,800
+200
+1% +$906 ﹤0.01% 101
2023
Q4 		$88.4K Buy
+17,600
New +$55.2K ﹤0.01% 201

Other funds holding IBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Carlson Capital Management's IBRX Position: Q4 2024 in Review

Carlson Capital Management increased its ImmunityBio (IBRX) stake by 5.3% in Q4 2024, buying an estimated $4.17K and bringing the position to 20,000 shares worth $51.2K. The position accounts for ﹤0.01% of the portfolio, ranked #111.

Carlson Capital Management first reported a position in IBRX in Q4 2023 and has held it in 5 quarters since. The position peaked at $118K in Q2 2024. 201 funds tracked by Wall St. Rank hold IBRX as of Q4 2024.

  • Carlson Capital Management held 20,000 shares of ImmunityBio worth $51.2K as of Q4 2024.
  • Carlson Capital Management bought 1,000 ImmunityBio shares in Q4 2024, an estimated $4.17K.
  • ImmunityBio made up ﹤0.01% of Carlson Capital Management's portfolio in Q4 2024, its #111 holding.
  • Carlson Capital Management first reported a position in ImmunityBio in Q4 2023 and has held it in 5 quarters since.
  • Carlson Capital Management's ImmunityBio position peaked at $118K in Q2 2024.
  • 201 funds tracked by Wall St. Rank held ImmunityBio as of Q4 2024.

Based on Carlson Capital Management's 13F filing for Q4 2024, filed 10 Feb 2025.